DEAR1 could help treatment decisions for patients with early-onset disease, according to PLoS Medicine paper.
A gene called DEAR1 is an independent predictor of local recurrence in early-onset breast cancers, according to a team from the University of Texas M. D. Anderson Cancer Center.
In this study, the researchers used a suppression subtractive hybridization on chromosome 1 in a region where loss of heterozygosity regularly occurs. They found a new gene and called it ductal epithelium-associated RING Chromosome 1, or DEAR1. Analysis of 14 samples showed that DEAR1 protein expression was reduced or lost in 71% of ductal carcinomas in situ. Sequence analysis of 55 primary breast tumors showed that 13% contained genetic alterations in DEAR1.
Additionally, the scientists found that DEAR1 expression was frequently lost in women with early-onset breast cancer. Loss of DEAR1 expression correlated with a strong family history of breast cancer and with a breast cancer subtype that has a poor outcome. At five-year follow-up of a cohort of 123 premenopausal women with onset of breast cancer between the ages of 25 and 49 years, DEAR1-positive expression correlated significantly with a 95% local recurrence-free survival.
Reporting in PLoS Medicine in a paper called “DEAR1 Is a Dominant Regulator of Acinar Morphogenesis and an Independent Predictor of Local Recurrence-Free Survival in Early-Onset Breast Cancer,” the authors suggest that “DEAR1-negative staining on immunohistochemistry could be an important marker to stratify early-onset breast cancer patients for increased vigilance in follow-up and adjuvant therapy.”
Agendia Offers Prognostic Tool for Breast Cancer (Sep. 5, 2008)
Qiagen and Center for Molecular Medicine Team Up to Identify Breast Cancer Diagnostic Markers (Feb. 18, 2008)
Over 50 New Breast Cancer Biomarkers Discovered (Dec. 20, 2007)
Glycominds and Fox Chase Cancer Center Partner to Discover Breast Cancer Diagnostic Blood Test (Oct. 25, 2007)
New Breast Cancer Biomarkers Identified (Dec. 27, 2006)